CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.341
EU - Europa 7.785
AS - Asia 6.408
SA - Sud America 1.084
AF - Africa 146
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 22
Totale 37.815
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.152
GB - Regno Unito 2.589
SG - Singapore 2.009
CN - Cina 1.683
IT - Italia 1.197
HK - Hong Kong 1.157
BR - Brasile 904
DE - Germania 753
SE - Svezia 695
IE - Irlanda 434
VN - Vietnam 423
UA - Ucraina 415
RU - Federazione Russa 362
PL - Polonia 357
TR - Turchia 347
FI - Finlandia 267
FR - Francia 212
BG - Bulgaria 189
ID - Indonesia 179
IN - India 168
CA - Canada 109
JP - Giappone 94
AR - Argentina 67
IQ - Iraq 60
MX - Messico 47
NL - Olanda 45
BD - Bangladesh 41
BE - Belgio 39
ES - Italia 39
LT - Lituania 39
EG - Egitto 33
KR - Corea 33
AT - Austria 31
EC - Ecuador 31
MY - Malesia 30
ZA - Sudafrica 29
PK - Pakistan 24
VE - Venezuela 24
MA - Marocco 23
TW - Taiwan 22
AU - Australia 21
RO - Romania 19
EU - Europa 17
IR - Iran 17
CL - Cile 16
UZ - Uzbekistan 15
CH - Svizzera 14
CO - Colombia 14
CZ - Repubblica Ceca 14
MD - Moldavia 14
TN - Tunisia 14
SA - Arabia Saudita 13
PY - Paraguay 11
IL - Israele 10
DO - Repubblica Dominicana 9
JO - Giordania 9
KE - Kenya 9
PE - Perù 9
NO - Norvegia 8
NP - Nepal 8
PH - Filippine 8
PT - Portogallo 8
AE - Emirati Arabi Uniti 7
KZ - Kazakistan 7
NZ - Nuova Zelanda 7
SN - Senegal 7
AZ - Azerbaigian 6
GH - Ghana 6
HU - Ungheria 6
DZ - Algeria 5
MT - Malta 5
UY - Uruguay 5
A2 - ???statistics.table.value.countryCode.A2??? 4
GR - Grecia 4
JM - Giamaica 4
LU - Lussemburgo 4
OM - Oman 4
PA - Panama 4
PS - Palestinian Territory 4
QA - Qatar 4
TT - Trinidad e Tobago 4
AL - Albania 3
AM - Armenia 3
AO - Angola 3
BO - Bolivia 3
BZ - Belize 3
CG - Congo 3
ET - Etiopia 3
IS - Islanda 3
LB - Libano 3
LK - Sri Lanka 3
MK - Macedonia 3
MN - Mongolia 3
SK - Slovacchia (Repubblica Slovacca) 3
BH - Bahrain 2
BW - Botswana 2
CR - Costa Rica 2
DK - Danimarca 2
EE - Estonia 2
GE - Georgia 2
Totale 37.777
Salva come PNG Salva come JPEG
Città #
Fairfield 3.260
Ashburn 1.970
Woodbridge 1.816
Santa Clara 1.811
Southend 1.682
Houston 1.463
Seattle 1.281
Singapore 1.259
Chandler 1.195
Hong Kong 1.147
Cambridge 1.028
Wilmington 1.017
Jacksonville 744
Ann Arbor 736
Dearborn 736
London 486
Nyköping 473
Beijing 459
Dublin 429
Warsaw 347
Modena 310
San Diego 243
Dallas 231
Izmir 219
New York 206
Los Angeles 195
Princeton 188
Sofia 188
Eugene 174
Council Bluffs 169
Jakarta 157
The Dalles 142
Hefei 132
Helsinki 129
Chicago 126
Moscow 115
Shanghai 115
Dong Ket 103
Buffalo 99
Ho Chi Minh City 99
Falls Church 85
Columbus 83
Hanoi 81
Munich 77
São Paulo 75
Milan 73
Boardman 64
Bremen 63
Fremont 63
Tokyo 62
Redwood City 56
Phoenix 54
Frankfurt am Main 49
Ottawa 47
Salt Lake City 47
Guangzhou 45
Redondo Beach 39
Baghdad 37
San Giuliano Milanese 36
Bologna 35
Brussels 35
Lauterbourg 34
Brooklyn 30
Rome 30
Norwalk 29
Belo Horizonte 28
Rio de Janeiro 28
Atlanta 27
Mumbai 27
Orem 27
Poplar 26
Seoul 25
Turku 25
Nuremberg 23
Lawrence 22
Toronto 22
Asyut 21
Denver 21
Düsseldorf 21
Brasília 20
Chennai 20
Kilburn 20
Tampa 20
Nanjing 19
Chiswick 18
Jinan 18
Paris 18
Portsmouth 18
Florence 17
Kunming 17
Montreal 17
Curitiba 16
Des Moines 16
Hangzhou 15
Mexico City 15
Stockholm 15
Banqiao 14
Campinas 14
Johannesburg 14
Parma 14
Totale 28.706
Salva come PNG Salva come JPEG
Nome #
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 551
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 516
GD2 expression in breast cancer. 379
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 379
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 360
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 351
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 347
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 331
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 319
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 317
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 314
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 311
BRAF ,NRASandC-KITAdvanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival 308
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 294
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 284
M09Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 282
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 282
Quality of life and anxious-depressive symptoms in cancer patients undergoing mindfulness-based interventions: Feasibility and preliminary outcomes on prospective single-centre case-control study (MIND4ME St.) 281
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 277
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 277
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 277
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 274
5-Fluorouracil pharmacogenomics: still rocking after all these years? 273
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 271
Transient sunitinib resistance in gastrointestinal stromal tumors. 268
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 268
Il trattamento di prima e seconda linea nel carcinoma gastrico 267
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 262
Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma 261
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 260
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 260
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 258
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 257
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 257
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 256
The evolving role of microsatellite instability in colorectal cancer: A review 249
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 248
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 247
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 247
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials 246
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 241
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 241
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 238
Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 236
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 235
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 234
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer 233
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 233
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 233
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 232
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 231
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 229
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 228
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 226
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 225
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 224
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 224
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel 223
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 223
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 222
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 221
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 219
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma 218
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 217
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 217
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 216
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 214
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 213
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 211
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 210
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 209
Male mammary myofibroblastoma: Two case reports and brief review of literature 209
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 207
Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs) 207
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 206
The Italian Rare Pancreatic Exocrine Cancer Initiative 205
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 204
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 204
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 204
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 202
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 202
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 201
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 201
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 201
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 201
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 200
Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. 197
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 197
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 197
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors 195
Progress of molecular targeted therapies for advanced renal cell carcinoma. 194
Selecting the best treatment for an individual patient. 194
Reply to O. Corli et al and M. Lucchesi et al 194
A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC) 194
Bone metastases- Pharmacological treatment 193
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 193
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 193
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. 191
Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? 191
Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response 191
Totale 24.710
Salva come PNG Salva come JPEG
Categoria #
all - tutte 151.333
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 151.333
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.177 0 0 0 0 0 469 420 647 307 567 376 391
2021/20223.569 237 431 328 152 98 248 184 192 381 351 654 313
2022/20233.576 418 361 223 319 411 422 54 283 771 44 150 120
2023/20242.059 77 117 116 194 425 121 256 350 43 54 95 211
2024/20256.909 276 93 122 463 1.458 1.051 494 463 835 404 420 830
2025/20265.114 687 279 885 1.105 1.564 594 0 0 0 0 0 0
Totale 38.162